|
|
|
|
|
10.03.26 - 15:42
|
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained (24/7 Wall St.)
|
|
|
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target, while assigning a Hold and a $350 price target to Amgen Inc. (NASDAQ:AMGN). Meanwhile, JPMorgan maintained its Overweight rating on clinical-stage oncology company Oric Pharmaceuticals Inc. (NASDAQ:ORIC) ... Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
The post Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained appeared first on 24/7 Wall St.....
|
|
|
10.03.26 - 13:12
|
Here Are Tuesday′s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: Futures are trading modestly lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday. That was the biggest spike in oil pricing since 2020. With the retreat in the black gold, the major indices did a ... Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's, Qualcomm, Rivian, Strategy and More
The post Here Are Tuesday's Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe's, Qualcomm, Rivian, Strategy and More appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
05.03.26 - 20:09
|
McRae Industries, Inc. Dividend Declared (PR Newswire)
|
|
|
MOUNT GILEAD, N.C., March 5, 2026 /PRNewswire/ -- McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) declared a dividend of $.14 per share on the Company's Class A and Class B Common Stock payable on April 1, 2026 to shareholders of record on March 18, 2026. View original......
|
|
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 13:48
|
3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations (Business Wire)
|
|
|
Villarreal-Barragan brings global experience delivering first-in-human and complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companiesSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms. Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors.
“Rebeca brings a strong track record of building and leading clinical operations in both established biopharma organizations and emerging biotechnology companies,” said Behzad Kharabi, M.D., chief medical officer of 3T Biosciences. “Her pragmatic, quality-focused approach and experience delivering complex early phase clinical trials will be an important asset as we progress ou...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.02.26 - 20:01
|
Trade Uncertainty Rattles Global Stock Markets | Open Interest 2/23/2026 (Bloomberg)
|
|
|
Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." Trade uncertainty rattles markets again as President Trump moves forward with sweeping new global tariffs following a Supreme Court decision. We speak to Rep. Jason Smith, the Chairman of the House Ways and Means Committee about what's next. Plus, the CEOs of Mazda North America and Freeport-McMoRan join Bloomberg Open Interest to talk about the impact on their businesses. Novo plunges. Merck splits. Gilead makes a deal. We're tracking a flurry of pharma headlines this morning. And Blue Owl's selloff is deepening fears about liquidity risks inside the $1.8 trillion private credit market. (Source: Bloomberg)...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
